Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01808144 · ClinicalTrials.gov registry record · Phase 3
Lesinurad and Febuxostat Combination Extension Study in Gout
A Phase 3 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT01808144: Completed Phase 3 study, sponsored by Ardea Biosciences.
NCT01808144 is a Phase 3 study that has completed, run by Ardea Biosciences. The registered enrollment target is 196 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01808144, a Phase 3 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.
Primary Outcome
Percentage of participants in Study 307 With sUA \< 5.0 mg/dL from the Core Studies 304 and Extension Study 307 - Observed Cases
Interventions
- DRUG lesinurad
- DRUG febuxostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2013-03-01 |
| Est. Completion | 2016-10-06 |
| Phase | Phase 3 |
What the finished NCT01808144 record still lists
NCT01808144 is an interventional study that assigns participants to a tested intervention. The registered 196 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which lesinurad is the first listed.
NCT01808144 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01808144 about?
NCT01808144 is a clinical study titled "Lesinurad and Febuxostat Combination Extension Study in Gout". This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.
What is the current status of trial NCT01808144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2013-03-01. Estimated completion is 2016-10-06.
What interventions are being tested in trial NCT01808144?
The interventions under investigation include: lesinurad (DRUG), febuxostat (DRUG).
Who is sponsoring clinical trial NCT01808144?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01808144's enrollment target sits among peer trials
196 1390th of 2000 higher than 608 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02822768 · 196 participants · NA
Packing Versus no Packing for Cutaneous Abscess
- NCT04250259 · 196 participants · Phase 2
SAMe Trial for Patients With Alcoholic Cirrhosis
- NCT05142592 · 196 participants · Phase 1
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- NCT05317832 · 196 participants · Phase 2
Using Smartphones to Improve Physical Activity Levels of Individuals With Spinal Cord Injury
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI